TY - JOUR T1 - Cohort characteristics and chronic lung allograft dysfunction (CLAD) adjudication in a FP-7 funded project, systems prediction of CLAD (SysCLAD) JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - 1429 AU - Christophe Pison AU - Angela Koutsokera AU - Adrien Tissot AU - Karine Botturi AU - Christian Benden AU - John-David Aubert AU - Antoine Roux AU - Martine Reynaud-Gaubert AU - Romain Kessler AU - Sacha Mussot AU - Claire Dromer AU - Véronique Boussaud AU - Jean-François Mornex AU - Olivier Brugière AU - Marcel Dahan AU - Christiane Knopp AU - Florian Ernst AU - Andreas Fritz AU - Gustavo Olivera-Botello AU - Kévin Deplanche AU - Charles Auffray AU - Pierre-Joseph Royer AU - Michel Sève AU - Antoine Magnan AU - Laurent Nicod AU - Consortium SysCLAD Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/1429.abstract N2 - Background: CLAD including restrictive allograft syndrome (RAS) and bronchiolitis obliterans syndrome (BOS)is the main limitation in long-term survival after lung transplantation (LT); no predictive model of CLAD exists.Methods: SysCLAD is a prospective study of LT in 14 centers by merging STCS3 and COLT1 prospective cohorts including “clinicome”, environmental pollution, lung microbiome, exome sequencing, blood and BAL proteomics, blood transcriptomics and immunological assays collected at months 6 and 12 post LT to identify signature or biomarkers that will predict CLAD by year-3 post LT by a systems medicine approach (Pison et al. Eur Respir J 2014;43:689). Based on FEV1, FVC, TLC, FEV1/FCV, clinical files and CT (Verleden et al. JHLT 2014;33:127), a SysCLAD multidisciplinary adjudication committee held 3 times in 2013 identified by year-3, 4 phenotypes: stable, BOS, RAS and mix-RAS as RAS with an obstructive ventilatory defect.Results: between 2008 and 2013, 1 050 LT recipients were included. The first 425 patients were analysed: 51% male, 45±16 yrs old, 32±17 months follow-up, survival at 1, 2, 3, 4 and 5-year of 88, 82, 78, 76, 69% respectively. Among the 143 reaching 3 years alive we identified 83 stables, 38 BOS, 16 RAS and 6 mixed RAS cases, as a “novel” phenotype.Conclusion: By 2013, 1050 LT within 14 clinical centres were included in SysCLAD with a complete data base allowing to define 4 robust phenotypes by year-3 post LT: stable, BOS, RAS, mixed RAS, essential step in SysCLAD to promote a prediction within year-1 post LT before any decline in lung function. Funds from VLM, PHRC, STCS, FP-7. ER -